Oxaliplatin Medac

Oxaliplatin, the active ingredient in Oxaliplatin Medac, is a platinum‑based chemotherapy presented as a solution for intravenous use. It treats colorectal cancer and other solid tumours in adult patients. GNH USA supplies Oxaliplatin Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Oxaliplatin Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Oxaliplatin is a platinum‑based agent used in the treatment of cancers that respond to DNA‑damaging chemotherapy.

- Colorectal cancer: Improves survival and reduces tumour size in adjuvant and metastatic settings. - Gastric cancer: Used in combination regimens to enhance response rates. - Pancreatic cancer: Contributes to tumour control when combined with other cytotoxics. - Ovarian cancer: Added to standard regimens for improved disease control. - Esophageal cancer: Utilised in multi‑drug protocols for tumour reduction. - Small‑cell lung cancer: Employed as part of combination therapy to increase response.

Oxaliplatin may elicit a range of adverse reactions, from mild to severe, depending on individual tolerance and treatment context.

Common Side Effects: - Nausea and vomiting: Frequently reported during and after infusion. - Peripheral neuropathy: Tingling or numbness, often dose‑dependent. - Diarrhoea: May occur during treatment cycles. - Fatigue: Generalised tiredness common in chemotherapy. - Thrombocytopenia: Reduced platelet counts observed in labs. - Elevated liver enzymes: Mild transaminase rise detectable in blood tests.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: Anaphylaxis or bronchospasm during infusion. - Acute hemolytic anemia: Rapid destruction of red blood cells. - Severe neutropenia: Marked drop in neutrophil count increasing infection risk. - Cardiotoxicity: Rare cardiac dysfunction or arrhythmia. - Pulmonary toxicity: Interstitial lung disease or pneumonitis. - Renal failure: Acute kidney injury in susceptible patients.

When handling Oxaliplatin Medac, clinicians should observe specific safety measures and patient monitoring protocols.

- Renal function assessment: Baseline and periodic creatinine testing recommended. - Hepatic function monitoring: Liver enzymes should be checked before each cycle. - Neuropathy surveillance: Evaluate sensory changes before and during therapy. - Hematologic monitoring: CBC with differential prior to each infusion. - Pregnancy and lactation warning: Contra‑indicated unless benefits outweigh risks. - Store at ambient temperature: Keep vials in original packaging, protect from light and moisture.

Oxaliplatin can interact with several concomitant medications, altering its efficacy or toxicity profile.

Major Interactions (Avoid): - Aminoglycoside antibiotics: May increase nephrotoxic risk. - High‑dose vitamin C: Potentially reduces platinum‑DNA binding. - Concomitant platinum agents: Cumulative toxicity concerns.

Moderate Interactions (Monitor Closely): - Antiemetics 5‑HT3 antagonists: May affect infusion‑related nausea control. - Loop diuretics: Require renal function monitoring. - Anticoagulants: Increased bleeding risk with thrombocytopenia.